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Clinical evaluation of a capture ELISA for detection of proteinase-3
antineutrophil cytoplasmic antibody. Technical Note. Detection of an-
tineutrophil cytoplasmic antibodies (ANCA) has become a useful tool in
the diagnosis of Wegener’s granulomatosis and microscopic polyangiitis.
However, the results obtained with indirect immunofluorescence (IIF)
and by ELISA for ANCA demonstration do not always correlate. A
possible explanation for this finding could be that proteins are denatured
during the process of antigen purification or during coating onto the solid
phase. To avoid this possibility, a monoclonal antibody to PR3 that is
precoated on the plate can be used. In the present study we have used the
monoclonal antibody (MoAb) 4A3 for the capture of PR3 in an ELISA,
and a clinical evaluation of the diagnostic properties of the new capture
ELISA has been made. The sensitivity of the capture PR3-ANCA ELISA
was 85% in a material of c-ANCA positive sera. A specificity of 90% was
obtained in analyses from patients having various forms of glomerulone-
phritis. There was a significantly higher diagnostic sensitivity of the
capture PR3-ANCA ELISA (85%) compared to c-ANCA by IIF (58%) in
patients with Wegener’s granulomatosis with renal involvement. Capture
PR3-ANCA and direct ELISA for MPO-ANCA together gave a diagnos-
tic sensitivity of 98%, versus 75% using IIF. In conclusion, the capture
PR3-ANCA ELISA seems to be a valuable tool in the diagnosis of
Wegener’s granulomatosis with renal involvement. Preliminary data sug-
gest that the technique may have an advantage over direct ELISA for
PR3-ANCA, as well as in the follow-up of c-/PR3-ANCA associated
vasculitides. However, further prospective studies are needed to clarify
this premise.
The detection of antineutrophil cytoplasmic antibodies
(ANCA) has become an established diagnostic tool for patients
with small vessel vasculitis, such as Wegener’s granulomatosis
(WG) and microscopic polyangiitis (MP) [1–4]. Early diagnosis is
of paramount importance, since systemic small vessel vasculitides
often have a progressive course that rapidly results in an increased
extent and severity of organ involvement. ANCA analyses are
widely used today, the standard method most often being indirect
immunofluorescence (IIF) using ethanol-fixed human neutrophils
as substrate. By this method two patterns can be seen, a granular
cytoplasmic pattern (c-ANCA) and a perinuclear (p-ANCA)
pattern. The c-ANCA pattern, most often associated with WG, is
mainly caused by antibodies directed against proteinase 3 (PR3)
[5], although according to some reports the c-ANCA pattern can
sometimes be caused by antibodies directed against myeloperox-
idase (MPO) [6]. Several antigens have been described as giving
rise to a p-ANCA pattern: MPO, lactoferrin, elastase and cathep-
sin G [7, 8]. Besides, anti-nuclear antibodies may generate a
p-ANCA pattern if purified neutrophils are used as the sole
substrate [9].
The results obtained by IIF and by enzyme-linked immunosor-
bent assay (ELISA) for ANCA demonstration do not always
correlate. Some patients can be positive by ELISA and negative
by IIF and vice versa. The reason for this discrepancy is not
known. A possible explanation could be that proteins are dena-
tured during the process of antigen purification or during coating
onto the solid phase, thereby hiding or destroying conformational
epitopes on PR3 [10]. To avoid this, a plate precoated with a
monoclonal antibody (MoAb) can be used to capture the antigen.
A capture ELISA for PR3-ANCA, using MoAb 1E8, has recently
been evaluated [11] and in another study three MoAbs (4A3, 4A5
and 6A6) recognizing different epitopes on PR3 [12] have been
used in three capture assays [13]. The MoAb 4A3 presented the
PR3 antigen in such a way that 98% of all antibodies that most
likely were directed to PR3 were detected. The corresponding
numbers for the other two monoclonal antibodies were 87% for
MoAb 4A5 and 83% for MoAb 6A6, and when the monoclonals
were mixed the results showed less than 100% sensitivity. Thus,
we decided to use the MoAb 4A3, which showed the highest
sensitivity.
The aim of this study was to further evaluate the clinical
significance of a capture PR3-ANCA ELISA as a sero-diagnostic
tool for patients with primary small vessel systemic vasculitis. This
study was mainly focused on PR3-ANCA/c-ANCA and compared
the results obtained by IIF, conventional direct ELISA and
capture ELISA, respectively.
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METHODS
Direct PR3-ANCA and MPO-ANCA ELISA
Microtiter plates coated with isolated human neutrophil PR3
[14] or MPO [15] were obtained from Wieslab AB (Lund,
Sweden) and the analyses performed as described earlier [16].
For purification of PR3, human neutrophils from buffy coats
were fragmented by nitrogen bomb cavitation and the nuclei
removed by centrifugation [17]. The cytoplasmic material ob-
tained from the nitrogen bomb cavitation was separated on a
Percoll gradient into plasma membrane, azurophilic granulae and
specific granulae fractions. PR3 was extracted from the azuro-
philic granulae by Triton x-100. Negatively charged proteins were
then removed by ion exchange chromatography (DEAE-Sepha-
rose; Pharmacia, Uppsala, Sweden). Unbound proteins including
PR3 were separated on a S-200 gel filtration column (Pharmacia)
and PR3 eluted as the major peak. This preparation appeared to
be homogenous by SDS-PAGE with PR3 migrating as a 29 kDa
triplet.
Capture PR3 ANCA ELISA
The method described by Baslund et al was followed, [13].
MoAb 4A3 at a concentration of 1 mg/ml was coated to microtiter
plates at room temperature for 16 hours in carbonate buffer at pH
9.6. After washing in 0.15 M NaCl, 0.05% Tween 20 three times,
purified PR3 at a concentration of 1 mg/ml in PBS was incubated
at room temperature for 60 minutes and the plates were washed.
Sera, diluted 1:80 in PBS with 0.1% BSA and 0.05% Tween 20,
were incubated in duplicate wells for 60 minutes at room temper-
ature, and after washing bound IgG was detected by alkaline
phosphate-conjugated anti-human IgG (Orion Diagnostica, Hel-
sinki, Finland). To exclude nonspecific binding and rheumatoid
factor binding, a control plate was coated with an unrelated
monoclonal antibody of the same mouse Ig subclass and the
absorbance values of this plate were subtracted from the absor-
bance values obtained on the anti-PR3 coated plate for each
individual well. A serum was regarded as positive if the absor-
bance was . 3 SD higher than values obtained with healthy donor
sera (N 5 80). Values were related to a set of calibrators to
quantitate the values in arbitrary units/ml (AU/ml). Cut-off was
set at 8 AU/ml. If the absorbance of a sample was higher than the
highest calibrator it was diluted 10 times and reanalyzed before
calculating the unit’s value.
Intra-assay variability was 8%, calculated by testing one sample
16 times on the same run. Inter-assay variability was 8%, as
calculated by testing the same sample on 16 different runs.
All sera from 80 normal blood donors were negative in the
capture PR3-ANCA assay. The diagnostic specificity was calcu-
lated by testing sera from 112 patients with renal stones, 22
patients with Sjo¨gren’s syndrome, 18 with rheumatoid arthritis, 40
with systemic lupus erythematosus (SLE) and 88 with ulcerative
colitis. Only two sera were found to be positive in the capture
assay, both from patients with SLE. Specificity in this disease
control material was thus 99%.
Bactericidal/permeability-increasing protein-ANCA
Bacterial/permeability-increasing protein (BPI) was purified
from neutrophils and ANCA determination performed with direct
ELISA, using the techniques described by Zhao, Jones and
Lockwood [18].
Indirect immunofluorescence
Indirect immunofluorescence (IIF) was performed on ethanol-
fixed leukocytes according to a previously described standard
procedure [19]. In short, leukocytes from healthy blood donors
were fixed on glass slides in absolute ethanol at 4°C for five
minutes. Patient sera diluted 1:20 in PBS were incubated for 30
minutes at room temperature and bound IgG was detected by
FITC-conjugated rabbit anti-human IgG (Dako, Glostrup, Den-
mark).
Statistical methods
The following definitions were used.
Diagnostic sensitivity. The ability of the test to give a positive
finding when the person tested truly had the disease, that is, the
rate (%) positive results obtained in the assay out of all those
persons tested who had the disease. “Disease” implied a diagnosis
of WG.
Diagnostic specificity. The ability of the test to give a negative
finding when the person tested was free from the disease, that is,
the rate (%) negative result in the assay out of those without the
disease.
Positive predictive value (PPV). The true-positive rate, that is,
those with positive results and disease out of all those with
positive results in the test.
Negative predictive value (NPV). The false-negative rate, that is,
those with disease but a negative result in the assay out of all those
with negative results in the assay. PPV and NPV were made from
calculations on material C and D (see below, in the Materials
section).
The significance of differences in ANCA sensitivity between the
various ANCA assays was determined using the chi-square
method and Spearman’s rank correlation was used for calculation
of the correlation coefficient (Rho-value) between the titers
obtained by the ELISAs (AU/ml) and the corresponding values at
IIF (2, 1, 11, 111). The computer program used was Stat view
(1994; Abacus Concepts, Inc., Berkeley, CA, USA). The term
significant was used when P , 0.01.
Materials
To clinically evaluate the capture ELISA, four different patient
materials were investigated.
A. Sera from 80 patients, having typical c-ANCA by IIF in a
routine laboratory at Statens Serum Institut. To avoid bias in the
ELISA analysis, 40 IIF-negative sera that had been sent for IIF
screening for ANCA were included in a coded fashion. Clinical
data were not sought in this material. All the 120 sera were
analyzed in the capture ELISA for PR3-ANCA and in direct
ELISA for PR3- and MPO-ANCA. C-ANCA positive sera that
were negative in the ELISAs for PR3- or MPO-ANCA were
further analyzed in the BPI-ANCA ELISA.
B. Consecutive sera from 82 patients who had positive PR3-ANCA
in the capture ELISA. Clinical information was retrieved for all of
these patients and patients with a vasculitis were subgrouped
according to the nomenclature of the Chapel Hill consensus
conference [20], and for WG the criteria established by the
American College of Rheumatology [21] were used. Sera were
analyzed in direct ELISA for PR3-ANCA and MPO-ANCA as
well as with IIF for c-ANCA and p-ANCA.
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C. Sera from 52 patients with biopsy-proven glomerulonephritis in
whom sera had been drawn at the time of renal biopsy, stored at
220°C. This group included patients without small vessel vascu-
litis; 14 patients had endocapillary glomerulonephritis and 38 had
mesangioproliferative glomerulonephritis. All of these patients
had been referred to the Department of Nephrology at the
University Hospital of Lund for a renal biopsy. All of them had
pathological findings in the urinary specimen, such as renal
granular casts, microscopic hematuria and significant proteinuria
or a decreased glomerular filtration rate. Since mesangioprolif-
erative glomerulonephritis can present with a rather quiescent
clinical picture, we only included patients with a serum creatinine
above 100 mmol/liter in this subgroup. No such creatinine level
was used as inclusion criteria for the subgroup of endocapillary
glomerulonephritis. For the whole material, the serum creatinine,
median value, was 126 (range 68 to 1295) mmol/liter. Sera were
analyzed in capture ELISA for PR3-ANCA, direct ELISA for
PR3-ANCA and MPO-ANCA and by IIF for c-ANCA and
p-ANCA.
D. Sera from 48 consecutive patients with WG with renal involve-
ment. All patients have been referred to, examined and treated by
physicians in the Department of Nephrology at the University
Hospital of Lund. The diagnosis of WG implied granulomatous
inflammation in the respiratory tract either histologically proven
or strongly indicated by non-invasive diagnostic procedures (for
example, nodular pulmonary infiltrates on chest x-ray, or bone
destruction of the maxillary sinus) [19]. Renal biopsies revealed a
crescentic glomerulonephritis in 39 of the patients, a necrotizing
in four and a proliferative in five (of which granulomata was
detected in one), all together with a pauci-immune glomerulone-
phritis at immunofluorescent staining. Thus, renal involvement
was 100%, pulmonary involvement was recorded in 70% and
upper respiratory involvement in 55%. Seventy percent of the
cases had involvement of at least two organ systems besides the
renal. Median age was 58 years (range 31 to 77) and median
serum creatinine 300 mmol/liter (range 62 to 1300). All sera were
drawn at the time of renal biopsy, stored at 220°C and available
for the present analyses.
RESULTS
The results of ANCA detected by IIF, by direct and capture
ELISA in the four analyzed materials are presented in Table 1.
Ability of ELISA technique to detect PR3-ANCA in c-ANCA
positive sera
The percentage of positives by the direct and the capture
PR3-ANCA ELISA, respectively, compared with c-ANCA posi-
tivity was calculated from the material A and comprised 80
c-ANCA positive and 40 c-ANCA negative sera (Table 1). The
positive frequency of the direct PR3-ANCA ELISA was 78% (62
of 80) and of the capture PR3-ANCA ELISA was 85% (68 of 80).
Eight out of the 12 sera found to be positive by IIF but negative
in capture ELISA for PR3-ANCA had BPI-ANCA, and thus 10%
of the c-ANCA positive sera were explained by the presence of
BPI-ANCA.
Seven of the 40 c-ANCA negative sera revealed positive
PR3-ANCA by the capture assay. Three out of these 7 sera also
reacted in the BPI-ANCA ELISA. None of the 120 sera analyzed
contained detectable MPO-ANCA.
Ability of indirect immunofluorescence to detect PR3-ANCA in
capture PR3-ANCA positive samples
Data on positivity of ANCA by IIF versus PR3-ANCA positivity
were obtained from analysis of the 82 patients in material B
containing sera found to be positive by the capture PR3-ANCA
ELISA (Table 2). C-ANCA was detected in 55 and p-ANCA in 7
out of the 82 sera. Thus, the assay sensitivity for c-ANCA was 67%
(55 of 82), and for c-ANCA and p-ANCA together, 76% (62 of
82) towards capture ELISA.
Seventy-four out of the series of 82 consecutive patients who
had PR3-ANCA by the capture ELISA were found to have a
clinical diagnosis of WG or MP. Eight patients consequently had
“false positive” capture PR3-ANCA. Two of these false positive
sera were also c-ANCA positive, and these two sera were from
patients with clinical periarteritis nodosa and polymyalgia rheu-
matica, respectively. The diagnoses of the remaining six false-
positive sera are seen in Table 2.
As shown in Table 2, WG was diagnosed in 65 of the 82
patients. The percentage of positives from the direct ELISA for
PR3-ANCA in this subcohort of WG patients was 92% (60 of 65)
and for c-ANCA IIF 82% (50 of 65). Seventeen of the 74 capture
PR3-ANCA positive sera from patients with WG or MP had no
detectable ANCA by IIF.
Thus, the diagnostic sensitivity of c-ANCA and p-ANCA in
patients with WG or MP, from this material, was 57 of 74 (77%).
Table 1. Detection of antineutrophil cytoplasmic antibody (ANCA) by indirect immunofluorescence (IIF) for cytoplasmic or perinuclear staining
ANCA (c-ANCA and p-ANCA), by direct ELISA for proteinase 3 ANCA (PR3-ANCA) and myeloperoxidase-ANCA (MPO-ANCA), and by
capture ELISA for PR3-ANCA, in stored sera from four different groups of patients, A, B, C and D (see Materials)
Number of sera
positive/number of
sera analyzed %
A. c-ANCA
positive sera
B. PR3-ANCA
positive sera in
capture ELISA
C. Disease control sera
from patients with
glomerulonephritis
D. Patients with
Wegener’s
granulomatosis
Number of sera 80a 82 52 48
IIF c-ANCA 55/82 (67%) 3/52 (6%) 28/48 (58%)
IIF p-ANCA 0/80 (0%) 7/82 (8%) 6/52 (12%)b 8/48 (17%)
Capture PR3-ANCA 68/80 (85%) 5/52 (10%) 41/48 (85%)
Direct PR3-ANCA 62/80 (78%) 70/82 (85%) 0/52 (0%) 35/48 (73%)
Direct MPO-ANCA 0/80 (0%) not done 2/52 (4%) 6/48 (12%)
a Material in group A consisted of 80 sera with c-ANCA by IIF and 40 sera without detectable ANCA by IIF
b Two of the 6 p-ANCA positive sera also had MPO-ANCA by the ELISA
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Diagnostic specificity
The diagnostic specificity was already found to be 99% towards
a disease control material consisting of sera from patients with
Sjo¨gren’s syndrome, rheumatoid arthritis, SLE, ulcerative colitis
and renal stones.
The diagnostic specificity of the capture ELISA for PR3-ANCA
was especially studied using disease control sera from 52 patients
(material C) with endocapillary or mesangioproliferative glomer-
ulonephritis. “False positive” results were obtained with the
capture ELISA in 5 out of the 52 sera (9.6%). Four of the five
false positive sera manifested PR3-ANCA levels at the lower
range of positivity (9, 10, 15 and 15 AU/ml). By the direct ELISA
none of these five sera had PR3-ANCA. One of the five false
positive sera was also positive for c-ANCA by IIF, two for
p-ANCA and one for antinuclear antibody (ANA). In another six
sera IIF ANCA were demonstrated (two c-ANCA and four
p-ANCA), but these were negative in the capture ELISA. There-
fore, the diagnostic specificity of the capture ELISA for PR3-
ANCA was 90% (47 of 52), of the direct ELISA 100% (52 of 52),
and of the IIF for c-ANCA 94% (49 of 52) towards patients with
glomerulonephritis. There were no significant statistical differ-
ences in diagnostic specificity between the three assays (P 5 0.08).
Specificity was 83% (43 of 52) for c-ANCA and p-ANCA to-
gether, as judged from this glomerulonephritis control material.
Diagnostic sensitivity
The diagnostic sensitivity for PR3-ANCA in the capture ELISA
in patients with a clinical diagnosis of WG was assessed from the
material of consecutive patients with an established diagnosis of
WG having renal involvement (material D).
As shown in Table 3, 41 out of the 48 patients (85%) with WG
were positive for PR3-ANCA by the capture assay. The corre-
sponding number for the direct PR3-ANCA assay was 35 of 48 of
the patients (73%), and for the IIF c-ANCA 28 of 48 (58%).
There was a significantly higher diagnostic sensitivity of the
capture PR3-ANCA ELISA compared to IIF for c-ANCA (P 5
0.003).
There was a somewhat better correlation between ANCA levels
obtained by capture PR3-ANCA ELISA and c-ANCA by IIF (r 5
0.607, P 5 0.002) than between direct ELISA and c-ANCA (r 5
0.572, P 5 0.004).
P-ANCA was demonstrated in another 8 patients with WG, and
thus the overall sensitivity for c-ANCA and p-ANCA in patients
with WG was 75% (36 of 48). MPO-ANCA was found in six
patients with WG. The diagnostic sensitivity for the detection of
ANCA by the direct MPO-ANCA ELISA combined with the
capture PR3-ANCA ELISA was higher (98%; 47 of 48), than that
obtained for c-ANCA and p-ANCA (75%; 36 of 48; P 5 0.001).
Only one of the patients with WG had no detectable ANCA
either by ELISA or by IIF. Double positive sera were found in six
patients with WG. Four of these patients had p-ANCA as well as
high levels of MPO-ANCA, together with a low PR3-ANCA level
by the capture ELISA, but negative PR3-ANCA by the direct
ELISA. The two other double-positive sera from patients with
WG showed a c-ANCA pattern at IIF and high concentrations of
PR3-ANCA by both the capture and direct ELISA, together with
a low level of MPO-ANCA.
Two sera demonstrated a c-ANCA pattern but had MPO-
ANCA according to ELISA, and another three sera showed a
Table 2. Clinical diagnoses in 82 consecutive patients from whom sera had been found positive in the capture assay for PR3-ANCA
Clinical diagnosis N
PR3-ANCA capture
ELISA
PR3-ANCA direct
ELISA
MPO-ANCA
IIF
Level N Level N Type of pattern N
Wegener’s granulomatosis 65 263 6 158a 65 139 6 17a 60 0 c-ANCA 50
p-ANCA 3
ANA 1
Negative 11
Microscopic polyangiitis 9 122 6 121a 9 45 6 15a 8 c-ANCA 3
p-ANCA 1
Negative 5
Polyarteritis nodosa (classical) 1 131 52 0 c-ANCA
Polymyalgia rheumatica 1
renal carcinoma
1 460 174 0 c-ANCA
Systemic lupus erythematosus 1 31 0 0 p-ANCA1ANA
Limited skin vasculitis 1 32 0 0 0
Diabetes mellitus 1 88 0 0 p-ANCA1ANA
(centromere)
Diabetes mellitus 1 11 0 0 0
Lung cancer 1 38 0 0 0
Oligodendrioma 1 32 0 14 p-ANCA
Numbers of patients and levels of PR3-ANCA by capture and direct ELISA and direct MPO-ANCA ELISA are shown in comparison to indirect
immunofluorescence (IIF) findings; numbers of positive sera and type of IIF pattern; perinuclear (p-ANCA), cytoplasmic (c-ANCA), antinuclear
(ANA).
a Mean values and standard deviation
Table 3. Diagnostic sensitivity of ANCA using capture PR3-ANCA
ELISA, direct PR3-ANCA and MPO-ANCA ELISA and c-ANCA and
p-ANCA by IIF in 48 patients with Wegener’s granulomatosis, having
renal involvement at the time of diagnosis
ANCA method
Wegener’s granulomatosis
N 5 48
c-ANCA 28 (58%)
p-ANCA 8 (17%)
IIF-ANCA negative 12 (25%)
Capture PR3-ANCA ELISA 41 (85%)
Direct PR3-ANCA ELISA 35 (73%)
Direct MPO-ANCA ELISA 6 (12%)
ELISA ANCA negative 1 (2%)
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p-ANCA at IIF and PR3-ANCA by the direct as well as the
capture ELISA.
Calculation of positive and negative predictive values
From materials C and D, consisting of the 52 patients with
glomerulonephritis without vasculitis and the 48 patients with
WG, the calculated positive predictive value (PPV) for capture
PR3-ANCA ELISA, vis-a`-vis WG, was 89% (41 of 46) and the
negative predictive value (NPV) vis-a`-vis WG was 87% (47 of 54;
Table 4).
As shown in Table 4, the corresponding numbers for the
detection of PR3-ANCA by direct ELISA were: PPV 100% (35 of
35) and NPV 82% (52 of 65). The PPV for c-ANCA detection by
IIF was 90% (28 of 31) and the NPV was 71% (49 of 69).
Calculated on material B, the PPV for a positive PR3-ANCA by
capture ELISA vis-a`-vis WG or MP was 90% (74 of 82).
PR3-ANCA ELISAs in the follow-up of a patient with
Wegener’s granulomatosis
Figure 1 shows the levels of PR3-ANCA, analyzed by capture
and direct ELISA, respectively, during a follow-up of 39 months in
a patient with WG. The patient was a woman of 57 when the
diagnosis of WG was made, with involvement of the upper and
lower respiratory tract, eyes and kidneys. Induction therapy was
instituted with oral cyclophosphamide and prednisolone, and
remission was achieved after three months. A relapse was re-
corded in April 1994 with involvement of the eyes, manifested as
retinal vasculitis together with fever, arthralgia and raised CRP
levels. Due to severe side effects of the cytotoxic drugs, therapy
with trimethoprim-sulfamethoxazole was started. There was im-
provement but not complete remission, and intravenous immuno-
globulin therapy was added in the spring of 1995. A short period
of remission followed. A new relapse occurred in July 1995 with
involvement of the respiratory tract and later the kidneys. Inten-
sified treatment with plasma exchange combined with corticoste-
roid pulses and cyclophosphamide orally was given and the patient
went into remission after four months of intensive immunosup-
pression. In January 1997 a new relapse developed with epistaxis,
muscular pain and decreased renal function.
As shown in Figure 1 the levels of PR3-ANCA assayed by the
direct ELISA seemed to be associated with the first event of
relapse, with a raised level prior to the relapse, but later no
distinct increase could be measured. In contrast, the PR3-ANCA
level by the capture ELISA rose prior to the second and third
relapses. The levels of PR3-ANCA levels were obviously much
higher when assessed by the capture than with the direct ELISA
technique.
DISCUSSION
Since it is of vital importance to make the diagnosis of WG and
MP as early as possible in order to start therapy for the prevention
of extensive organ damage with subsequent loss of organ function
[2, 22, 23], it is crucial to have a serological ANCA test with a high
diagnostic sensitivity. However, therapy for vasculitic disease
implies the use of immunosuppressive treatment with the poten-
tial for toxic side effects, and therefore one must also consider the
diagnostic specificity of the tests.
Our results showed that the capture PR3-ANCA ELISA had an
acceptably high diagnostic sensitivity when analyzing sera from
patients with WG (85%), as well as a sensitivity of 85% in a series
of sera that all demonstrated a c-ANCA pattern at IIF. Combin-
ing the capture ELISA for PR3-ANCA with the direct ELISA for
MPO-ANCA gave a very high diagnostic sensitivity (98%) in our
cohort of patients with WG. The sensitivity then obtained was
higher than by using direct ELISA for both PR3- and MPO-
ANCAs (85%). In fact, the diagnostic sensitivity for the combined
use of capture PR3-ANCA and MPO-ANCA ELISA was higher
than that obtained for IIF c-ANCA and p-ANCA (75%). A
capture technique for PR3-ANCA detection has previously been
used by others [3, 11, 24]. In the study by Merkel et al (1997) 23
of 26 sera from patients with a known PR3-ANCA positive
vasculitis were found to be positive by their capture PR3-ANCA
ELISA [11]. However, they used the same monoclonal anti-PR3
catching antibody to control for background as well as for
anti-mouse IgG, and the reactivity of the serum to the monoclonal
antibody alone was subtracted from the reactivity to the mono-
clonal antibody-PR3 complex. Such a procedure may render
“false low” results, since a previous study has shown that patients
with WG have complexes of PR3 and PR3-ANCA and such
complexes may readily attach to the monoclonal anti-PR3 alone
[25].
Although a higher diagnostic sensitivity was found with the
capture technique than by IIF, there was an almost equal speci-
ficity by the capture PR3-ANCA ELISA and c-ANCA at IIF.
Regarding the specificity, we found it interesting to note that
three patients with glomerulonephritis, lacking clinical signs of
small vessel vasculitis, had both PR3-ANCA by the capture
ELISA as well as a c-ANCA pattern by IIF. Since we have not
followed up these patients, we cannot rule out the possibility of
future development of WG or MP in these three cases. On the
other hand, ANCAs have been demonstrated in some patients
with various forms of glomerulonephritis not associated with
vasculitis [26].
To achieve a higher specificity for the capture ELISA an
elevation of the cut-off level could be used. For example, a cut-off
of 15 AU/ml instead of the 8 AU/ml used in the present study
would have resulted in a higher specificity but an almost un-
changed diagnostic sensitivity (96% and 85%, respectively, data
Table 4. Results from analyses of sera from patients with vasculitic
disease (Wegener’s granulomatosis, N 5 48), and from patients without
vasculitic disease (glomerulonephritis, N 5 52), using capture ELISA
for PR3-ANCA, direct ELISA for PR3-ANCA and IIF for c-ANCA
Disease
1 2 S
Capture ELISA
PR3-ANCA 1 41 5 46
PR3-ANCA 2 7 47 54
S 48 52 100
Direct ELISA
PR3-ANCA 1 35 0 35
PR3-ANCA 2 13 52 65
S 48 52 100
IIF
c-ANCA 1 28 3 31
c-ANCA 2 20 49 69
S 48 52 100
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not presented). Applying a cut-off level of 15 AU/ml in “material
B” would, however, entail a false negative test in two patients with
WG and one with MP.
It is known that PPV and NPV give more important informa-
tion about a diagnostic test than the diagnostic sensitivity and
diagnostic specificity. The PPV for the capture PR3-ANCA
ELISA vis-a`-vis WG seemed to be quite acceptable (89%, and the
NPV 87%), considering that the values obtained have neither
been calculated towards healthy controls nor towards non-renal
disease controls. We have calculated the PPV and NPV from a
material consisting of patients with WG and another “disease
free” (that is, without signs of a vasculitic disease) material
consisting of patients with glomerulonephritis. All the patients
were recruited from the same geographical region, all had a renal
biopsy performed on a uniform program for investigation, and all
were collected during the same period of time as the patients with
WG. Some would prefer a disease control material consisting of
patients with rapidly progressive glomerulonephritis lacking vas-
culitis such as WG and MP. However, several studies have shown
a quite high prevalence of ANCA in materials like this [27–29].
Besides, the treatment for rapidly progressive glomerulonephritis
does not differ in the acute phase for those with a small vessel
vasculitis and those without [30]. In patients with mesangioprolif-
erative and endocapillary glomerulonephritis, the clinical presen-
tation of renal findings can be much the same as in WG or MP,
that is, microscopic hematuria, mild proteinuria, granular casts in
the urine and decreased renal function. However, the treatment
differs in these different groups, which augment the demand for a
reliable serological test. Obviously it is more harmful to start
immunosuppressive therapy in a patient with endocapillary glo-
merulonephritis, particularly if it is associated with a bacterial
infection, which is not always clinically overt, than in a patient with
extracapillary glomerulonephritis that is not associated with WG
or MP.
In the cohort of patients with WG there were two with c-ANCA
who had MPO-ANCA in the ELISA. Such a finding has been
described earlier [6]. Three patients had a p-ANCA by IIF and
PR3-ANCA by ELISA, and sera from these three patients were
further assayed for antibodies to elastase, cathepsin G, lactoferrin,
BPI, lysozyme and azurocidin by ELISA (results not shown). All
three sera were negative in these ELISAs, two of the samples
manifested a high background, perhaps explaining the weak
p-ANCA at IIF staining. One patient demonstrated a combined
pattern of both c-ANCA and p-ANCA at IIF. He was a 57-year-
old man with MP, 64% crescents in the renal biopsy, and with
PR3-ANCA by the capture method as well as the direct ELISA.
Such a finding with both c-and p-ANCA has occasionally been
described earlier [31].
The IIF ANCA pattern could be caused by antibodies to
antigens other than PR3 or MPO, as also shown in this study
where 10% of c-ANCA positivity was caused by BPI-ANCA.
The explanation for the findings of not reaching full concor-
dance in prevalence of ANCA by the capture PR3-ANCA ELISA
and direct PR3-ANCA ELISA could be that the capture assay
makes it possible to detect different or other PR3 epitopes.
Several sera with a low or moderate level of PR3-ANCA in the
direct ELISA manifested very high levels in the capture ELISA,
supporting the impact of different epitopes. As depicted in Figure
1, we found an association in PR3-ANCA levels measured by the
capture technique with clinical relapses in one case. No such
relationship could be demonstrated by the direct ELISA after the
event of the first relapse. It is still debatable if rises in the serum
levels of ANCA, after the initial onset of the disease, reflect
disease activity [32–34]. Our present case that exhibited elevated
levels of PR3-ANCA by capture ELISA prior to relapse may
indicate a better correlation with ANCA directed to a particular
epitope revealed by this capture method, thus indicating a better
clinical significance for the capture assay in single patients. One
could speculate if there is a change in epitope specificity over time
relating to type or duration of immunosuppression. However,
future prospective longitudinal studies are needed to clarify these
questions.
Fig. 1. Patient with Wegener’s granulomatosis:
levels (in Au/ml) of proteinase 3 antineutrophil
cytoplamic antibody (PR3-ANCA) using direct
and capture ELISA assay, respectively, in
relation to clinical presentation of relapses,
and serum creatine levels during a 39 month
follow-up. Symbols are: (L) levels of PR3-
ANCA measured by direct ELISA; (f) levels
of PR3-ANCA measured by capture ELISA;
() serum creatinine 3 10 mmol/liter.
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APPENDIX
Abbreviations used in this article are: ANCA, antineutrophil cytoplas-
mic antibodies; BPI, bactericidal/permeability increasing protein; ELISA,
enzyme-linked immunosorbent assay; IIF, indirect immunofluorescence;
MoAb, monoclonal antibody; MP, microscopic polyangiitis; MPO, myelo-
peroxidase; NPV, negative predictive value; PPV, positive predictive
value; PR3, protease 3; WG, Wegener’s granulomatosis.
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